Tivozanib hydrochloride hydrate is a selective and orally active VEGFR tyrosine kinase inhibitor with IC 50 of 0.21, 0.16, 0.24 nM for VEGFR-1 , VEGFR-2, VEGFR-3 , respectively. Tivozanib hydrochloride hydrate inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib hydrochloride hydrate has the potential for the research of metastatic renal cell carcinoma (RCC) . In Vitro Tivozanib hydrochloride hydrate inhibits the phosphorylation of VEGFR-1, VEGFR-2 and VEGFR-3. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Tivozanib hydrochloride hydrate (1 mg/kg; p.o.; 14 days) suppresses the development of CNV lesions and leds to a significant regression of established CNV, reducing the affected areas by 67.7%. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Tivozanib hydrochloride hydrate
CAS number：682745-41-1 molecular formula：C22H22Cl2N4O6
overview
compound introduction
Specs
| Chinese alias | 盐酸替沃扎尼布水合物 | ||
| English alias | KRN951 hydrochloride hydrate | AV-951 hydrochloride hydrate | ||
| CAS number | 682745-41-1 | molecular formula | C22H22Cl2N4O6 |
| molecular weight | 509.34 g/mol | Exact mass | - |
| PSA | 109.000 Ų | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
